Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children--a multicentered evaluation of dosage and safety.
Clinical trials of monovalent A/USSR/77 (H1N1) and trivalent A/USSR/77 (H1N1), A/Texas/77 (H3N2), and B/Hong Kong/72 inactivated influenza virus vaccines were carried out in 358 children and adolescents. Only split-virus vaccines were administered to children younger than 13 years of age. No serious local or systemic reactions were observed among the study participants. Two doses of vaccine containing 7-20 micrograms of the A/USSR/77 (H1N1) viral antigen were required to achieve serum titers of hemagglutinin-inhibiting (HA1) antibody greater than 1:40. However, single doses containing 7-20 micrograms of the A/Texas/77 (H3N2) or B/Hong Kong/72 antigens stimulated serum HAI antibody levels of 1:40.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004306:Dose-Response Relationship, Immunologic; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D009980:Influenza A virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D014613:Vaccines, Attenuated
D000914:Antibodies, Viral; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated